A Double-Blind Randomized Phase III Trial Of The Safety and Efficacy Of CPP-1X / Sulindac Compared with CPP-1X Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP)

Brief Description Of Study

This study intends to compare the effectiveness, safety and pharmacokinetics (meaning the "behavior" of the medicine once it is inside of your body) of the medicines CPP-1X (a drug in Phase III trials) combined with sulindac (a drug already approved by the FDA), versus CPP-1X and sulindac medications alone. The medications will be evaluated over a 24 month treatment period in patients with Familial Adenomatous Polyposis (FAP). The study is randomized, and double-blind. We are treating patients diagnosed with FAP, who are also positive for the APC mutation (meaning certain genes were "deleted" and/or "changed", making them act differently than how they are supposed to in the body), and are over the age of 18.

Clinical Study Identifier: 821135

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Double-Blind Randomized Phase III Trial Of The Safety and Efficacy Of CPP-1X / Sulindac Compared with CPP-1X Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP)
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.